Palvella Therapeutics Inc. (PVLA) Stock Price

115.175 ▲ +5.975 (+5.47%)
Open: 110.79 Vol: 17.4K Day's range: 109.50 - 115.24 May 20, 15:59 EDT
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
PVLA Technical Analysis
5 mins 30 mins Hourly Daily Weekly
BUY BUY BUY SELL NEUTRAL
  5 mins 30 mins Hourly Daily Weekly
MA5 114.40▲ 113.77▲ 114.03▲ 112.53▲ 120.23▼
MA10 113.95▲ 113.83▲ 112.26▲ 116.56▼ 120.66▼
MA20 113.80▲ 111.55▲ 109.07▲ 121.79▼ 110.08▲
MA50 113.66▲ 109.87▲ 115.14▲ 122.73▼ 81.49▲
MA100 111.43▲ 115.53▼ 119.57▼ 111.04▲ N/A    
MA200 108.57▲ 119.96▼ 123.66▼ 91.28▲ N/A    
  5 mins 30 mins Hourly Daily Weekly
MACD 0.113▲ 0.313▲ 1.204▲ -1.697▼ -1.976▼
RSI 63.769▲ 69.948▲ 60.476▲ 45.343▼ 56.256▲
STOCH 90.860▲ 75.895     92.055▲ 30.215     45.619    
WILL %R -2.961▲ -0.874▲ -0.491▲ -55.468     -49.201    
CCI 168.033▲ 95.952     92.123     -74.347     -81.551    
Latest Filters Detected On PVLA
▼ MA $PVLA MA(20) Crossed Below MA(50) Set Alert
▼ BREAK $PVLA Price Breaks 30 Days Low Set Alert
▼ BREAK $PVLA Price Breaks 20 Days Low Set Alert
▼ BREAK $PVLA Price Breaks 10 Days Low Set Alert
Palvella Therapeutics Inc. News
Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas
Monday, May 18, 2026 09:23 PM
Clinically significant angiokeratomas represent a rare, chronic and debilitating lymphatic malformation with no FDA-approved therapies and an estimated more than 50,000 diagnosed patients in the U.S.
Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026
Monday, May 18, 2026 09:23 PM
Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering ...
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the ...
Friday, May 15, 2026 04:50 AM
Palvella Therapeutics Inc. 100% of patients with bleeding at baseline demonstrated a statistically significant improvement on the Cutaneous Venous Malformations Investigator Globa ...
PVLA historical stock data
date open high low close volume
20/05/26 110.63 115.33 109.50 115.175 218,041
19/05/26 104.24 110.35 101.29 109.20 206,320
18/05/26 114.24 114.29 103.61 105.05 305,393
15/05/26 116.82 116.82 111.56 114.24 258,331
14/05/26 120.76 121.025 117.81 118.97 153,363
13/05/26 126.47 126.47 119.59 120.57 183,251
12/05/26 121.56 126.14 120.84 125.79 153,350
11/05/26 121.75 128.36 119.66 122.09 338,979
08/05/26 113.61 121.72 113.61 121.29 231,378
07/05/26 129.05 129.05 111.06 113.26 571,437
Quote Details
52wk Low:20.20
52wk High:151.18
Vol:17.4K
Avg Vol(3m):4.7M
1Y Chng:+353.44%
1M Chng:-11.54%
Add to Watch List
More Information
Index US Composite
Market Cap. 1.51B